Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 500,938 |
|
|||||
| News | - | ||||||
| Day High | 13.60 | Low High |
|||||
| Day Low | 13.29 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| TG Therapeutics Inc | TGTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.3971 | -2.84% | 13.5829 | 10:33:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.375 | 13.29 | 13.60 | 13.98 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,675 | 500,938 | $ 13.48 | $ 6,750,438 | - | 6.46 - 35.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:33:15 | 1,000 | $ 13.5829 | USD |
TG Therapeutics (TGTX) Options Flow Summary
TG Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.09B | 154.42M | - | 233.66M | 12.67M | 0.08 | 164.92 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TG Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TGTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 13.99 | 14.63 | 13.26 | 14.01 | 3,074,044 | -0.4071 | -2.91% |
| 1 Month | 15.56 | 15.60 | 13.26 | 14.35 | 2,627,133 | -1.98 | -12.71% |
| 3 Months | 16.39 | 19.0175 | 12.84 | 15.35 | 3,445,528 | -2.81 | -17.13% |
| 6 Months | 7.40 | 22.67 | 6.89 | 14.48 | 4,997,471 | 6.18 | 83.55% |
| 1 Year | 22.65 | 35.67 | 6.46 | 15.88 | 4,786,697 | -9.07 | -40.03% |
| 3 Years | 42.86 | 45.50 | 3.48 | 14.62 | 3,464,878 | -29.28 | -68.31% |
| 5 Years | 8.03 | 56.74 | 3.48 | 16.34 | 2,767,645 | 5.55 | 69.15% |
TG Therapeutics Description
| TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. |
